Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

RGX-104: Ph I started

January 12, 2017 12:46 AM UTC

Rgenix began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral RGX-104 in about 80 patients. Rgenix has exclusive, worldwide rights to RGX-104 from GlaxoSmithKline....

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article